What is Ticagrelor?
Ticagrelor is an antiplatelet medication used to prevent thrombotic events, such as heart attack or stroke, in patients with acute coronary syndrome [1]. It belongs to a class of drugs known as P2Y12 inhibitors [2].
When does Ticagrelor's patent expire?
The primary patent for ticagrelor, held by AstraZeneca, was set to expire in the United States in 2024 [1]. However, the landscape of patent protection for the drug is complex, with numerous secondary patents and ongoing legal challenges influencing market exclusivity [1].
Why are companies challenging Ticagrelor's patents?
Patent challenges are common in the pharmaceutical industry when the primary patent nears expiration, particularly for high-value drugs like ticagrelor. These challenges often aim to pave the way for generic versions to enter the market sooner. Companies may contest the validity or enforceability of secondary patents that could extend market exclusivity beyond the original patent term [1].
Can generic versions of Ticagrelor be available before the patent expiry?
The availability of generic ticagrelor is dependent on the outcomes of patent litigation. While the main patent may expire, other patents, including those related to formulation, manufacturing processes, or specific uses, could potentially extend exclusivity. If these secondary patents are successfully challenged or invalidated, generic manufacturers may be able to launch their products earlier [1].
How does Ticagrelor compare to other antiplatelet drugs?
Ticagrelor works by reversibly binding to the P2Y12 receptor on platelets, inhibiting adenosine diphosphate (ADP)-mediated platelet activation and aggregation [2]. This mechanism of action is similar to other P2Y12 inhibitors like clopidogrel and prasugrel, though differences in potency, onset of action, and reversibility exist [3]. Clinical trials have compared ticagrelor with other agents, showing varying efficacy and safety profiles depending on the patient population and specific outcome measured [3].
What are the main risks associated with Ticagrelor?
The primary risks associated with ticagrelor use include bleeding events, ranging from minor to severe and potentially life-threatening [1]. Dyspnea (shortness of breath) is another notable side effect [1]. Other potential risks include bradyarrhythmia and increased serum creatinine levels [1].
Where can I find more detailed information on Ticagrelor patents?
Detailed information regarding ticagrelor patents, including expiration dates, patent numbers, and legal challenges, can be found on specialized databases such as DrugPatentWatch.com [1].
Sources:
[1] https://drugpatentwatch.com/drugs/ticagrelor
[2] https://www.ncbi.nlm.nih.gov/books/NBK544328/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270419/